IRIX
IRIDEX Corporation
There isn't enough reported data to score IRIX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IRIX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IRIX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IRIX PE Valuation
IRIX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IRIX Forward outlook
There aren't enough analyst estimates for IRIX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IRIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.20 | +$0.13 |
| Q1 2026 | -$0.19 | +$0.24 |
| Q4 2025 | -$0.26 | +$0.28 |
| Q3 2025 | -$0.30 | +$0.37 |
| Q2 2025 | -$0.33 | +$0.33 |
| Q1 2025 | -$0.43 | +$0.24 |
| Q4 2024 | -$0.54 | +$0.05 |
| Q3 2024 | -$0.67 | -$0.19 |
IRIX is still losing money, but far less than before: $0.20 per share over the past year, against $0.73 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IRIX on earnings quality, reporting a profit while its opponent remains loss making.
IRIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12.6M | -7.4% |
| Q1 2026 | $11.8M | -0.8% |
| Q4 2025 | $14.7M | +16% |
| Q3 2025 | $12.5M | +7.8% |
| Q2 2025 | $13.6M | +7.4% |
| Q1 2025 | $11.9M | +1.1% |
| Q4 2024 | $12.7M | +1.9% |
| Q3 2024 | $11.6M | -9.9% |
IRIX's revenue fell from its 2022 peak and has held roughly level since: $13M last quarter, down 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -8.2% | -1.3 points |
| Q1 2026 | -2.8% | -1 points |
| Q4 2025 | -0.1% | +3.9 points |
| Q3 2025 | -11% | +4.8 points |
| Q2 2025 | -6.9% | +14 points |
| Q1 2025 | -1.7% | +26 points |
| Q4 2024 | -4% | +21 points |
| Q3 2024 | -16% | -3 points |
IRIX's operating margin was −8.2% last quarter, down 1.3 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IRIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IRIX on profitability, with a higher operating margin.
IRIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $124K | +$534K |
| Q1 2026 | -$1.4M | -$276K |
| Q4 2025 | $483K | +$1.7M |
| Q3 2025 | -$1.2M | +$1.9M |
| Q2 2025 | -$410K | +$916K |
| Q1 2025 | -$1.2M | +$491K |
| Q4 2024 | -$1.2M | -$300K |
| Q3 2024 | -$3.1M | -$1.2M |
IRIX has burned cash in almost every quarter: −$2M over the past year, against −$6M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IRIX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +107K shares |
| 1 year | +3.7% | +625K shares |
| 3 years | +8.6% | +1.4M shares |
| 5 years | +6.8% | +1.1M shares |
| Available history | +27% | +3.6M shares |
IRIX has 17M diluted shares, up 3.7% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IRIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IRIX Net Leverage
IRIX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IRIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.1 | Neutral |
| Stochastic | 20.8 | Neutral |
IRIX's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IRIX PE vs Healthcare Sector
IRIX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IRIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 1.4% below |
| 20 week MA | $0.79 | 10% below |
| 50 week MA | $1.02 | 30% below |
| 100 week MA | $1.11 | 36% below |
| 200 week MA | $1.68 | 58% below |
IRIX is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IRIX on trend strength, trading above more of its moving averages.
IRIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.35 | $1.94 | -17% |
| 2021 | $1.94 | $6.22 | +221% |
| 2022 | $6.22 | $2.11 | -66% |
| 2023 | $2.11 | $2.81 | +33% |
| 2024 | $2.81 | $1.67 | -41% |
| 2025 | $1.67 | $1.23 | -26% |
| 2026 YTD | $1.23 | $0.71 | -42% |
IRIX's yearly returns have swung widely, from +221% in 2021 to −66% in 2022. It's down 42% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IRIX on returns for 2026, with the stronger performance.